{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:24:13Z","timestamp":1773282253296,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[1995,12,1]],"date-time":"1995-12-01T00:00:00Z","timestamp":817776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[1995,12]]},"DOI":"10.1016\/s0161-6420(95)30798-1","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T14:30:49Z","timestamp":1381156249000},"page":"1743-1752","source":"Crossref","is-referenced-by-count":392,"title":["Effects on Intraocular Pressure and Side Effects of 0.005% Latanoprost Applied Once Daily, Evening or Morning"],"prefix":"10.1016","volume":"102","author":[{"given":"Albert","family":"Alm","sequence":"first","affiliation":[]},{"given":"Johan","family":"Stjernschantz","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0161-6420(95)30798-1_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1358\/dof.1992.017.08.187766","article-title":"Phenyl substituted prostaglandin analogs for glaucoma treatment","volume":"17","author":"Stjernschantz","year":"1992","journal-title":"Drugs Future"},{"key":"10.1016\/S0161-6420(95)30798-1_bib2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/jm00054a008","article-title":"Phenylsubstituted prostaglandins: potent and selective antiglaucoma agents","volume":"36","author":"Resul","year":"1993","journal-title":"J Med Chem"},{"key":"10.1016\/S0161-6420(95)30798-1_bib3","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1001\/archopht.1991.01080110100045","article-title":"PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers","volume":"109","author":"Alm","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib4","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/archopht.1993.01090100059027","article-title":"The effects on aqueous dynamics of PhXA41, a new prostaglandin F2\u03b1analogue, after topical application in normal and ocular hypertensive human eyes","volume":"111","author":"Ziai","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib5","first-page":"259","article-title":"Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2\u03b1-isopropyl ester analogues for glaucoma treatment","volume":"37","author":"Hotehama","year":"1993","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib6","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0161-6420(93)31482-X","article-title":"Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure: a one-month study","volume":"100","author":"Alm","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/S0161-6420(95)30798-1_bib7","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/archopht.1993.01090050096037","article-title":"Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure","volume":"111","author":"Fristr\u00f6m","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib8","first-page":"270","article-title":"Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma","volume":"37","author":"Hotehama","year":"1993","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib9","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0161-6420(13)31817-X","article-title":"Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: comparison of dose regimens","volume":"100","author":"Nagasubramanian","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/S0161-6420(95)30798-1_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archopht.1993.01090050091036","article-title":"Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2\u03b1analogue (PhXA41). An in-hospital, placebo-controlled study","volume":"111","author":"R\u00f3cz","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib11","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(93)31484-3","article-title":"Effects of PhXA41, a new prostaglandin F2\u03b1analog, on aqueous humor dynamics in human eyes","volume":"100","author":"Toris","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/S0161-6420(95)30798-1_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/bjo.79.1.12","article-title":"Latanoprost administered once daily causes a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol","volume":"79","author":"Alm","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib13","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/archopht.1987.01060080114039","article-title":"Pilocarpine antagonizes prostaglandin F2\u03b1-induced ocular hypotension in monkeys: evidence for enhancement of uveoscleral outflow by prostaglandin F2\u03b1","volume":"105","author":"Crawford","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0014-4835(89)90049-3","article-title":"Prostaglandin F2\u03b1increases uveoscleral outflow in the cynomolgus monkey","volume":"49","author":"Gabelt","year":"1989","journal-title":"Exp Eye Res"},{"key":"10.1016\/S0161-6420(95)30798-1_bib15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0014-4835(89)90011-0","article-title":"Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2\u03b1-1-isopropylester in the cynomolgus monkey","volume":"48","author":"Nilsson","year":"1989","journal-title":"Exp Eye Res"},{"key":"10.1016\/S0161-6420(95)30798-1_bib16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/bjo.76.4.214","article-title":"PhXA34-a prostaglandin F2\u03b1analogue. Effect on intraocular pressure in patients with ocular hypertension","volume":"76","author":"Villumsen","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bjo.73.6.419","article-title":"Prostaglandin F2\u03b1-isopropylester eye drops. Effects in normal human eyes","volume":"73","author":"Villumsen","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib18","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archopht.1992.01080240073034","article-title":"Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension","volume":"110","author":"Camras","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib19","first-page":"259","article-title":"Clinical efficacy of PhXA34 and PhXA41: two novel prostaglandin F2\u03b1-isopropyl ester analogues for glaucoma treatment","volume":"37","author":"Hotehama","year":"1993","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/S0161-6420(95)30798-1_bib20","first-page":"1","article-title":"The ocular effects of eicosanoids and other autacoids: Historic background and the need for a broader perspective","volume":"312","author":"Stjernschantz","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/S0161-6420(95)30798-1_bib21","first-page":"293","article-title":"Mediation of the ocular response to injury and irritation: Peptides versus prostaglandins","author":"Unger","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/S0161-6420(95)30798-1_bib22","first-page":"2463","article-title":"Prostanoid-induced blood-aqueous barrier breakdown in rabbits involves the EP2 receptor subtype","volume":"31","author":"Protzman","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/S0161-6420(95)30798-1_bib23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1358\/dof.1992.017.08.187766","article-title":"Phenyl substituted prostaglandin analogs for glaucoma treatment","volume":"17","author":"Stjernschantz","year":"1992","journal-title":"Drugs Future"},{"key":"10.1016\/S0161-6420(95)30798-1_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0161-6420(78)35673-6","article-title":"Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma","volume":"85","author":"Boger","year":"1978","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642095307981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642095307981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T23:38:10Z","timestamp":1564443490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642095307981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1995,12]]}},"alternative-id":["S0161642095307981"],"URL":"https:\/\/doi.org\/10.1016\/s0161-6420(95)30798-1","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[1995,12]]}}}